US Stock Market Move | Pfizer Inc. (PFE.US) fell more than 4%, with the company expecting a slowdown in revenue growth in 2026.

On Tuesday, Pfizer Inc. (PFE.US) fell more than 4% to $25.27. On the news front, Pfizer Inc. predicted that sales growth next year will be minimal or non-existent as the company is working on updating its popular drug product line through a series of expensive acquisitions. Pfizer Inc. said in a statement on Tuesday that it expects revenue in 2026 to be between $59.5 billion and $62.5 billion, roughly in line with Wall Street expectations. Sales for this year are expected to be $62 billion, consistent with the company's guidance in early November. The company forecasts adjusted earnings per share next year to be between $2.80 and $3. CEO Albert Bourla is facing a crucial moment in revitalizing Pfizer Inc. as the demand for the Covid-19 vaccine and treatment drugs that drove a surge in the company's sales a few years ago is starting to fade. Revenue from Covid-related products is still declining; Pfizer Inc. predicts that sales of these products will decrease by approximately $1.5 billion to $5 billion next year.